- Data Highlights TL32711 Induces Apoptosis in Acute Myeloid Leukemia (AML) Blast Cells and Eliminates AML Stem/Progenitor Cells -
MALVERN, Pa., Dec. 11, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the oral presentation of new data on its Smac mimetic drug candidate TL32711 at the 53rd ASH Annual Meeting and Exposition in San Diego. The study, conducted at The University of Texas M. D. Anderson Cancer Center, demonstrated that TL32711 induces apoptosis in acute myeloid leukemia (AML) cells, including AML stem/progenitor cells, alone and in combination with chemotherapy.
"TL32711 demonstrated single agent activity against blasts obtained from newly diagnosed AML patients and in CD34+38- stem/progenitor cells isolated from blasts of these patients, with no toxicity in CD34+ cells from normal bone marrows at doses effective against AML cells," said Michael Andreeff, M.D., Ph.D. Professor of Medicine and Chief, Molecular Hematology & Therapy, Departments of Leukemia and Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson Cancer Center. "When combined with various nucleoside analogues clinically used in AML therapy such as Ara-C, clofarabine, and demethylating agents decitabine and 5-azacytidine, TL32711 synergistically enhanced apoptotic cell death in AML cells and AML stem/progenitor cells."
TetraLogic recently announced the initiation of a Phase 1/2 clinical trial of TL32711 in elderly patients with AML. The investigator-initiated study is being conducted at the Hospital of the University of Pennsylvania and is an open-label, non-randomized trial that will evaluate the safety, tolerability and clinical response activity of TL32711 in patients aged 60 years or greater who have relapsed or primary refractory AML.
About TL32711
TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple Inhibitor of Apoptosis Proteins (IAPs). TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological malignancies as a monotherapy and in combination with other anti-cancer therapies. TL32711 is nearing completion of a single agent Phase 1 study in solid tumors and lymphomas and a Phase 1b five-arm combination clinical study in solid tumors. In the clinical studies to date, TL32711 has been well tolerated and exhibited rapid suppression of IAPs and antitumor activity.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker BioVentures, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company's Web site at www.tetralogicpharma.com.
Media Contact:
Russo Partners, LLC
Tony Russo, Ph.D., or Andreas Marathovouniotis
212-845-4251 or 212-845-5235
[email protected]
[email protected]
TetraLogic Pharmaceuticals
James Goldschmidt, Ph.D.
610-889-9900
SOURCE TetraLogic Pharmaceuticals